NCT04569825.

Study name	Effect of nasal steroid in the treatment of anosmia due to COVID‐19 disease
Methods	Parallel‐group randomised controlled trial
Participants	Individuals with a confirmed diagnosis of COVID‐19 (real‐time PCR) with recent onset of anosmia and or ageusia  Inclusion criteria: Adults, aged 18 years or over Proven case of COVID‐19 by real‐time PCR of nasopharyngeal/oropharyngeal swabs Recent onset of anosmia, with or without ageusia and other symptoms of COVID‐19 Exclusion criteria: Pregnant women Psychological disturbances Previous history of anosmia Severe sinonasal disease Previous sinonasal surgery Refusal to participate Lost to follow‐up Planned sample size: estimated enrolment 250 participants
Interventions	Intervention: intranasal opthamesone (steroid) drops (frequency and duration not stated) Comparator: intranasal normal saline drops (frequency and duration not stated)
Outcomes	Outcomes of interest in the review: Primary outcomes: Presence of normal olfactory function Recovery rate of anosmia, and time to recovery of anosmia (no further details provided) Serious adverse effects  Not reported Change in sense of smell Not reported Secondary outcomes: Prevalence of parosmia Not reported Change in sense of taste Not reported Disease‐related quality of life Not reported Other adverse effects (including nosebleeds/bloody discharge) Not reported Other outcomes reported by the study: No other outcomes are reported
Starting date	1 August 2020
Contact information	Raid M Al‐Ani Email: med.raed.alani2003@uoanbar.edu.iq
Notes	Estimated study completion date: 15 October 2020 Trial registered in Iraq Correspondence from the trial investigator confirms that all participants in this trial will have had recently diagnosed COVID‐19, and that symptoms of anosmia will have lasted for less than 2 weeks at the start of the trial.